GB2272375A - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GB2272375A GB2272375A GB9325480A GB9325480A GB2272375A GB 2272375 A GB2272375 A GB 2272375A GB 9325480 A GB9325480 A GB 9325480A GB 9325480 A GB9325480 A GB 9325480A GB 2272375 A GB2272375 A GB 2272375A
- Authority
- GB
- United Kingdom
- Prior art keywords
- iron
- pharmaceutically acceptable
- acceptable salt
- alginic acid
- metallic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition comprises alginic acid and/or its pharmaceutically acceptable salt and a metallic compound chosen from a group consisting of iron-ammonium alum, iron glycerophosphate, iron lactate, reduced iron, base bismuth nitrate, potassium alum, aluminium hydroxide, kaoline, barium sulphate, calcium gluconate, calcium chloride, calcium carbonate or their mixture, at the following ratio of the components in per cent by weight: alginic acid and/or its pharmaceutically acceptable salt 5-91, metallic compound the balance. The composition will find use for prophylaxis and treatment of gastro-intestinal disturbances, flesh wounds and as a hemostatic agent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU1992/000074 WO1993020826A1 (en) | 1992-04-10 | 1992-04-10 | Pharmaceutical composition |
Publications (3)
Publication Number | Publication Date |
---|---|
GB9325480D0 GB9325480D0 (en) | 1994-03-09 |
GB2272375A true GB2272375A (en) | 1994-05-18 |
GB2272375B GB2272375B (en) | 1996-02-14 |
Family
ID=20129712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9325480A Expired - Fee Related GB2272375B (en) | 1992-04-10 | 1992-04-10 | Pharmaceutical composition |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPH06508641A (en) |
DE (1) | DE4294862T1 (en) |
GB (1) | GB2272375B (en) |
NL (1) | NL9220019A (en) |
WO (1) | WO1993020826A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997036599A1 (en) * | 1996-03-29 | 1997-10-09 | Marcin Krotkiewski | Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1269826B (en) * | 1994-05-24 | 1997-04-15 | Paolo Minoia | USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS |
JP3114016B2 (en) * | 1998-05-15 | 2000-12-04 | 株式会社ホギメディカル | Wound hemostatic material having cell adhesion promoting effect |
GB9812278D0 (en) * | 1998-06-09 | 1998-08-05 | Bristol Myers Squibb Co | Use of a wound dressing in the treatment of acute wounds |
JP4712380B2 (en) * | 2002-07-26 | 2011-06-29 | 三笠製薬株式会社 | Topical preparation |
EP2298338B1 (en) | 2002-09-16 | 2012-08-22 | Agennix Incorporated | Lactoferrin compositions and methods of treatment of skin wounds |
PL2368554T3 (en) | 2003-04-08 | 2015-05-29 | Progenics Pharm Inc | Pharmaceutical formulations containing methylnaltrexone |
AR057325A1 (en) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
AR057035A1 (en) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
ES2540551T3 (en) | 2007-03-29 | 2015-07-10 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
ES2765811T5 (en) | 2007-03-29 | 2024-02-27 | Progenics Pharm Inc | Crystalline form of (R)-n-methylnaltrexone bromide and its uses |
PE20090700A1 (en) | 2007-03-29 | 2009-07-13 | Progenics Pharm Inc | HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR |
WO2009099411A1 (en) | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4391799A (en) * | 1980-02-15 | 1983-07-05 | The United States Of America As Represented By The Secretary Of The Army | Protective gel composition for treating white phosphorus burn wounds |
EP0206626A2 (en) * | 1985-06-13 | 1986-12-30 | Barry James Dr. Marshall | Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis |
US4935406A (en) * | 1988-09-20 | 1990-06-19 | Marion Laboratories, Inc. | Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders |
-
1992
- 1992-04-10 WO PCT/RU1992/000074 patent/WO1993020826A1/en active Application Filing
- 1992-04-10 DE DE4294862T patent/DE4294862T1/en not_active Withdrawn
- 1992-04-10 GB GB9325480A patent/GB2272375B/en not_active Expired - Fee Related
- 1992-04-10 NL NL9220019A patent/NL9220019A/en not_active Application Discontinuation
- 1992-04-10 JP JP5518208A patent/JPH06508641A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4391799A (en) * | 1980-02-15 | 1983-07-05 | The United States Of America As Represented By The Secretary Of The Army | Protective gel composition for treating white phosphorus burn wounds |
EP0206626A2 (en) * | 1985-06-13 | 1986-12-30 | Barry James Dr. Marshall | Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis |
US4935406A (en) * | 1988-09-20 | 1990-06-19 | Marion Laboratories, Inc. | Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997036599A1 (en) * | 1996-03-29 | 1997-10-09 | Marcin Krotkiewski | Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease |
Also Published As
Publication number | Publication date |
---|---|
WO1993020826A1 (en) | 1993-10-28 |
NL9220019A (en) | 1994-04-05 |
GB2272375B (en) | 1996-02-14 |
GB9325480D0 (en) | 1994-03-09 |
DE4294862T1 (en) | 1994-06-09 |
JPH06508641A (en) | 1994-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2272375A (en) | Pharmaceutical composition | |
MY109928A (en) | Fatty acid treatment | |
KR100261669B1 (en) | Substituted pyrazolylbenzene sulfonamides for the treatment of inflammation | |
CA2208078A1 (en) | Formulations and methods for reducing skin irritation | |
EP1078636A4 (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
GB1520197A (en) | Stable antibiotic compositions | |
AR004701A1 (en) | 2-AZETIDINONES SUBSTITUTED WITH SUGARS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOSITION, USE OF SUCH COMPOUNDS TO MANUFACTURE MEDICINES AND EQUIPMENT. | |
MY109531A (en) | Effervescent antacid | |
RS97703A (en) | Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparation containing said compounds | |
HU9403759D0 (en) | Substituted 1-oxo-1,2-dihydro-isoguino-linoyl- and 1,1-dioxo-2h-1,2-benzothiazinoyl-guanidines, process for producing them, use of them in therapy and pharmaceutical compositions containing them | |
CA2132416A1 (en) | Use of transglutaminase inhibitor for the treatment of scar tissue | |
CA2148194A1 (en) | Cyclopeptides of the formula i | |
IL111036A0 (en) | Beta_alanine derivatives, processes for the preparon thereof and pharmaceutical compositions containing the same | |
AU4603293A (en) | Antiperspirant actives and compositions | |
CA2137904A1 (en) | Psyllium Drink Mix Compositions | |
CA2298645A1 (en) | Use of physiologically acceptable vanadium compounds, salts and complexes | |
BG101192A (en) | Two- and three-component fungicidal mixtures | |
RU97102146A (en) | TWO AND THREE COMPONENT FUNGICIDAL MIXTURES | |
DE02748548T1 (en) | CALCIUM-L-THREONATE FOR PREVENTING OR TREATING BONE FRACTURES | |
CA2211177A1 (en) | Agent for acting upon bone formation disturbances containing alkaline citrates, lactates and/or malates | |
CA2067374A1 (en) | Osteogenesis promoter | |
AU6483286A (en) | Prazosin-pirbuterol combination for bronchoduation | |
WO1990001321A3 (en) | Method for treating and preventing loss of bone mass | |
IT1260151B (en) | Pharmaceutical composition useful for the treatment of gastroenteric diseases, wounds and burns and as a haemostatic agent | |
JPS5683415A (en) | Toothpaste with reduced salty taste |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19980410 |